All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.

OCEAN phase III trial: Why the initial efficacy observed with melflufen + dex has not improved OS

In this video, Sonneveld discusses results from the OCEAN phase III (NCT03151811), multi-center trial, comparing melphalan flufenamide (melflufen) + dexamethasone versus pomalidomide + dexamethasone.

 

Share: